Based on the Syndax Pharmaceuticals Inc stock forecast from 10 analysts, the average analyst target price for Syndax Pharmaceuticals Inc is USD 34.72 over the next 12 months. Syndax Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Syndax Pharmaceuticals Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Syndax Pharmaceuticals Inc’s stock price was USD 16.79. Syndax Pharmaceuticals Inc’s stock price has changed by -21.98% over the past week, -15.29% over the past month and +14.22% over the last year.
No recent analyst target price found for Syndax Pharmaceuticals Inc
No recent average analyst rating found for Syndax Pharmaceuticals Inc
Company Overview Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. Read Less
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearr...Read More
Frequently Asked Questions About Syndax Pharmaceuticals Inc (SNDX) Stock
Based on ratings from 10 analysts Syndax Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 14 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on SNDX's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for SNDX is USD 34.72 over the next 12 months. The maximum analyst target price is USD 49 while the minimum anlayst target price is USD 18.
Unfortunately we do not have enough data on SNDX's stock to indicate if its overvalued.
The last closing price of SNDX's stock was USD 16.79.
The most recent market capitalization for SNDX is USD 1.60B.
Based on targets from 10 analysts, the average taret price for SNDX is projected at USD 34.72 over the next 12 months.
This means that SNDX's stock price may go up by +106.77% over the next 12 months.
We can't find any ETFs which contains Syndax Pharmaceuticals Inc's stock.
As per our most recent records Syndax Pharmaceuticals Inc has 184 Employees.
Syndax Pharmaceuticals Inc's registered address is 35 Gatehouse Drive, Waltham, MA, United States, 02451.
You can get more information about it from Syndax Pharmaceuticals Inc's website at https://www.syndax.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Syndax Pharmaceuticals Inc (SNDX) Stock
Based on ratings from 10 analysts Syndax Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 14 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on SNDX's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for SNDX is USD 34.72 over the next 12 months. The maximum analyst target price is USD 49 while the minimum anlayst target price is USD 18.
Unfortunately we do not have enough data on SNDX's stock to indicate if its overvalued.
The last closing price of SNDX's stock was USD 16.79.
The most recent market capitalization for SNDX is USD 1.60B.
Based on targets from 10 analysts, the average taret price for SNDX is projected at USD 34.72 over the next 12 months.
This means that SNDX's stock price may go up by +106.77% over the next 12 months.
We can't find any ETFs which contains Syndax Pharmaceuticals Inc's stock.
As per our most recent records Syndax Pharmaceuticals Inc has 184 Employees.
Syndax Pharmaceuticals Inc's registered address is 35 Gatehouse Drive, Waltham, MA, United States, 02451.
You can get more information about it from Syndax Pharmaceuticals Inc's website at https://www.syndax.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SNDX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
